Florida Cancer Specialists Drs. Scott Lunin and Scott Tetreault Co-Author Phase 2 Study on Duvelisib for Indolent Non-Hodgkin Lymphoma
Florida Cancer Specialists Oncologists Published in the Journal of Clinical Oncology
Ft. Myers, FL – May 13, 2019… Two Florida Cancer Specialists physicians, Dr. Scott Lunin, who practices in Sarasota, and Dr. Scott Tetreault, who practices in Tallahassee, were co-authors of an important new study that was integral in gaining FDA approval for a new treatment for indolent (slow-growing) non-Hodgkin lymphoma (iNHL). The study, ‘DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma,’ was published in the April 10 issue of the Journal of Clinical Oncology.
As stated in the article, “Indolent non-Hodgkin lymphoma (iNHL) remains largely incurable and often requires multiple lines of treatment after becoming refractory to standard therapies. Duvelisib was approved by the Food and Drug Administration for relapsed or refractory (RR) chronic lymphocytic leukemia or small lymphocytic lymphoma (SLL) and RR follicular lymphoma (FL) after two or more prior systemic therapies.”
The recent FDA approval of duvelisib means that there are now several different treatment options for patients who have received two or more prior therapies. Prior to FDA approval of duvelisib, treatment resistance and cumulative toxicity limited the options for many patients, especially some older patients, “… whose comorbidities may preclude aggressive treatment and for whom dependence on hospitals and clinic visits for infusional therapies represents a significant challenge.
”The efficacy and manageable safety profile of duvelisib, which was demonstrated in the DYNAMO study, support its potential as a novel therapy for patients with refractory iNHL. To read the full study: https://ascopubs.org/doi/full/10.1200/JCO.18.00915
About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)
Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. In the past 4 years, the majority of new cancer drugs approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.* Trained in such prestigious medical schools and research institutes as Duke, Stanford, Harvard, Emory, M.D. Anderson, and Memorial Sloan Kettering, our physicians are consistently ranked nationally as Top Doctors by U.S. News & World Report.
Founded in 1984, FCS is one of the largest medical oncology/hematology practices in the United States. With more than 230 physicians, 220 advanced practice registered nurses (APRN) and physician assistants (PA) and nearly 100 locations in our network, we are committed to providing world-class cancer care in community-based settings, close to home.
Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies, genomic-based treatment, and immunotherapy. Our highest values are embodied by our outstanding team of highly-trained and dedicated physicians, clinicians and staff.
* Prior to approval
For More Information, Contact:
Florida Cancer Specialists & Research Institute
Shelly Glenn, Chief Marketing & Sales Officer
(813) 281.0088 ext. 327
Ganick Communications, Inc.